AU2013323198B2 - Dihydro-6-azaphenalene derivatives for the treatment of CNS, oncological diseases and related disorders - Google Patents

Dihydro-6-azaphenalene derivatives for the treatment of CNS, oncological diseases and related disorders Download PDF

Info

Publication number
AU2013323198B2
AU2013323198B2 AU2013323198A AU2013323198A AU2013323198B2 AU 2013323198 B2 AU2013323198 B2 AU 2013323198B2 AU 2013323198 A AU2013323198 A AU 2013323198A AU 2013323198 A AU2013323198 A AU 2013323198A AU 2013323198 B2 AU2013323198 B2 AU 2013323198B2
Authority
AU
Australia
Prior art keywords
substituted
unsubstituted
alkyl
disease
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013323198A
Other languages
English (en)
Other versions
AU2013323198A1 (en
Inventor
Srinivasa R. Cheruku
Jeffery A. Gladding
John W. Lee
Jean R. Loebelenz
Dieu Nguyen
James J. Norman
Craig ROSENFELD
Sambaiah Thota
John C. Warner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Babcock Institute for Green Chemistry LLC
Original Assignee
Warner Babcock Institute for Green Chemistry LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Babcock Institute for Green Chemistry LLC filed Critical Warner Babcock Institute for Green Chemistry LLC
Publication of AU2013323198A1 publication Critical patent/AU2013323198A1/en
Application granted granted Critical
Publication of AU2013323198B2 publication Critical patent/AU2013323198B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2013323198A 2012-09-28 2013-09-27 Dihydro-6-azaphenalene derivatives for the treatment of CNS, oncological diseases and related disorders Ceased AU2013323198B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261707444P 2012-09-28 2012-09-28
US61/707,444 2012-09-28
PCT/US2013/062429 WO2014052906A1 (en) 2012-09-28 2013-09-27 Dihydro-6-azaphenalene derivatives for the treatment of cns, oncological diseases and related disorders

Publications (2)

Publication Number Publication Date
AU2013323198A1 AU2013323198A1 (en) 2015-04-09
AU2013323198B2 true AU2013323198B2 (en) 2018-03-29

Family

ID=50385790

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013323198A Ceased AU2013323198B2 (en) 2012-09-28 2013-09-27 Dihydro-6-azaphenalene derivatives for the treatment of CNS, oncological diseases and related disorders

Country Status (10)

Country Link
US (1) US10047089B2 (enExample)
EP (1) EP2900239B1 (enExample)
JP (1) JP6345674B2 (enExample)
KR (1) KR20150060775A (enExample)
CN (1) CN104994853B (enExample)
AU (1) AU2013323198B2 (enExample)
BR (1) BR112015007095A8 (enExample)
CA (1) CA2886749A1 (enExample)
IL (1) IL237912B (enExample)
WO (1) WO2014052906A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106316966A (zh) * 2015-06-15 2017-01-11 董运勤 医药中间体n-(2-吡嗪甲基)苄胺磷酸盐化合物制备方法
CN108699019B (zh) * 2015-11-11 2022-05-10 华纳巴布科克绿色化学学院有限公司 用于治疗中枢神经系统和其他疾病的苯并呋喃衍生物
US11286233B2 (en) 2017-05-09 2022-03-29 Ambient Photonics, Inc. Stilbene derivatives for the treatment of CNS and other disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3614414A1 (de) * 1986-04-29 1987-11-05 Knoll Ag Neue benzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
JPH03232858A (ja) * 1990-02-07 1991-10-16 Toyo Pharma- Kk １，８―ナフタル酸イミド誘導体とその製法及び用途
US6417178B1 (en) 1994-07-19 2002-07-09 University Of Pittsburgh Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits
CA2332239A1 (en) * 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
US6380193B1 (en) 1998-05-15 2002-04-30 Guilford Pharmaceuticals Inc. Fused tricyclic compounds, methods and compositions for inhibiting PARP activity
US20040106548A1 (en) * 2001-09-07 2004-06-03 Schmidt Michelle A Conformationally constrained labeled peptides for imaging and therapy
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
WO2004105700A2 (en) * 2003-05-28 2004-12-09 Guildford Pharmaceuticals, Inc. Compounds, methods and pharmaceutical compositions for inhibiting parp
BRPI0615930A2 (pt) * 2005-09-15 2016-08-23 Painceptor Pharma Corp métodos de modular a interação de uma neurotrofina e um receptor de neurotrofina, de tratar dor em um indivíduo, de tratar distúrbio inflamatório em um indivíduo, de tratar um distúrbio neurológico em um indivíduo, e de tratar uma doença ou distúrbio associado aos sistemas geniturinário e/ou gastrointestinal de um indivíduo, e, composto
FR2927077B1 (fr) * 2008-01-31 2012-05-25 Commissariat Energie Atomique Derives du 1,8-naphtalimide en tant qu'agents de scintillation notamment pour la discrimination entre les neutrons rapides et les rayons gamma
CN102603695B (zh) * 2012-02-10 2014-06-18 山东大学 一种氨基酸-荧光团类化合物及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CLAYDEN J ET AL, "Cyclization of lithiated pyridine and quinoline carboxamides: synthesis of partially saturated pyrrolopyridines and spirocyclic beta-lactams", ORGANIC LETTERS, 2005, vol. 7, no. 17, pages 3673 - 3676 *

Also Published As

Publication number Publication date
CN104994853A (zh) 2015-10-21
CN104994853B (zh) 2018-11-30
AU2013323198A1 (en) 2015-04-09
IL237912B (en) 2019-08-29
BR112015007095A8 (pt) 2019-08-20
KR20150060775A (ko) 2015-06-03
CA2886749A1 (en) 2014-04-03
EP2900239A1 (en) 2015-08-05
EP2900239A4 (en) 2016-04-20
WO2014052906A1 (en) 2014-04-03
JP2015531379A (ja) 2015-11-02
BR112015007095A2 (pt) 2017-07-04
EP2900239B1 (en) 2019-03-20
IL237912A0 (en) 2015-05-31
JP6345674B2 (ja) 2018-06-20
US10047089B2 (en) 2018-08-14
US20140094487A1 (en) 2014-04-03

Similar Documents

Publication Publication Date Title
DE60316542T2 (de) 7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungen
EP2501696A2 (en) Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
JPH0647586B2 (ja) １−ヘテロアリ−ル−４−〔（２．５−ピロリジンジオン−１−イル）アルキル〕ピペラジン誘導体
AU2007278041B2 (en) Labelled analogues of halobenzamides as radiopharmaceuticals
KR20050049520A (ko) 신경 활성 화합물
JP2656699B2 (ja) 置換ベンジルアミノキヌクリジン
CN113563319B (zh) 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物
US10300155B2 (en) Alpha-synuclein ligands
IE61007B1 (en) New amino-5,6,7,8-tetrahydronaphto (2,3-b)furan derivatives, the processes for preparing them and the pharmaceutical compositions which contain them
EP2900239B1 (en) Dihydro-6-azaphenalene derivatives for the treatment of cns, ocular diseases and related disorders
US7148240B2 (en) Aminoalkoxybenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same
KR20100031610A (ko) 아데노신 Ａ3 수용체 리간드로서의 트리아졸로[1,5-ａ]퀴놀린
US10519143B2 (en) Substituted-indole-compounds as estrogen receptor down-regulators
US20110064662A1 (en) Kit for producing molecular probe for pet screening for drug discovery
JP2024525166A (ja) Ｎ－置換フェニルスルホンアミド系化合物およびその用途
WO2010059549A1 (en) Prolyl hydroxylase inhibitors
US6946483B2 (en) Aminoalkenylbenzoyl-benzofuran or benzothiophene, method for preparing same and compositions containing same
BG64555B1 (bg) Бис(акридинкарбоксамид) и бис(феназинкарбоксамид) като антитуморни агенти
CN117567480B (zh) 银杏内酯b衍生物及其盐，及其制备方法和用途
EP3166930A1 (en) 4-oxo-1,4-dihydroquinoline-3-carboxamide as selective ligand for cannabinoid receptor 2 for diagnosis and therapy
US20240228467A1 (en) Indirubin compounds and methods thereof
Lee et al. Synthesis and evaluation of stilbenylbenzoxazole and stilbenylbenzothiazole derivatives for detecting β-amyloid fibrils
KR100892251B1 (ko) 베타아밀로이드 집적체 및 피브릴에 우수한 결합력을가지는 화합물 및 이의 제조 방법
US20260027118A1 (en) Compositions useful for modulating splicing
JPH0521910B2 (enExample)

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired